NEOTHETICS, INC. (NASDAQ:NEOT) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On December7, 2017, Neothetics, Inc. (the “Company”) entered into a Twelfth Amendment to the Lease (the “Lease Amendment”) with LJ Gateway Office LLC (the “Landlord”), dated December4, 2017.The Lease Amendment amends the Lease dated July3, 2008, as amended (collectively, the “Lease”), for the office space located at Suite No.270, 9171 Towne Centre Drive, San Diego, California containing approximately 11,107 rentable square feet (the “Original Premises”) and additional space consisting of approximately 3,580 rentable square feet located at Suite No.250, 9171 Towne Centre Drive, San Diego, California (the “New Premises”). The Company currently occupies the New Premises as its headquarters while subleasing the entire Original Premises to Abacus Data Systems, Inc. (“Abacus”) to the terms of the Sublease Agreement dated January31, 2017.
The Lease Amendment provides for a termination of the lease with respect to the approximately 11,107 rentable square feet located at Suite No.270, 9171 Towne Centre Drive, San Diego, California. The termination is contingent upon the mutual execution and delivery of a new lease between an affiliate of Landlord and Abacus, which the Company expects to occur in the first quarter of 2018..
The foregoing description of the terms of the Lease Amendment and Sublease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, which has been filed previously by the Company with the Securities and Exchange Commission (the “SEC”) as an exhibit to its Registration Statement on Form S-1 filed on October17, 2014, the Eleventh Amendment to the Lease and Sublease, which has been filed previously by the Company with the SEC as an exhibit to its Form 8-K filed on February10, 2017, and the Lease Amendment, of which a copy is filed as an exhibit hereto.
| Item 1.01. | Financial Statements and Exhibits |
(d)Exhibits.
-2-
Neothetics, Inc. ExhibitEX-10.1 2 d447131dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 TWELFTH AMENDMENT THIS TWELFTH AMENDMENT (the “Amendment”) is made and entered into as of December 4,…To view the full exhibit click here
About NEOTHETICS, INC. (NASDAQ:NEOT)
Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. It has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.
